Table 1.
Characteristics of 26 patients on study
| Patient and Tumor Characteristics | Prior Treatment Characteristics | |||
|---|---|---|---|---|
| Sex | ||||
| Male | 9 | Initial diagnosis: | Patients | |
| Female | 17 | Unresectable at diagnosis | 10 | |
| Recurrence following surgery | 16 | |||
| Age (yrs) | Recurrence after 2nd surgery | 3 | ||
| At diagnosis | 29.5 | |||
| At presentation | 31 | At presentation: unresectable or resectable by amputation | 26 | |
| Location: | Adjuvant Radiation | 4 | ||
| Intra-Abdominal | 12 | |||
| Extremity | 6 | Systemic therapy | 15 | |
| Trunk/Chest wall | 6 | NSAIDS | Not analyzed | |
| Head and neck | 2 | Hormone | 8 (best response, SD) | |
| Liposomal Doxorubicin | 8 | Best response: 4 SD**. | ||
| Characteristics (radiological) | Doxorubicin | 4 | ||
| Multifocal | 7 | Decarbazine | 4 | |
| Diffuse | 20 | Methotrexate | 2 | |
| Nodular | 6 | Cyclophosphamide | 2 | |
| Imatinib or Sunitinib | 6 (1 pt with minor response***) | |||
| Size | ||||
| < 5 cm (T1) | 4 | Sorafenib | ||
| 5 – 10 cm (T2) | 11 | Progression on imaging | 23 pts | |
| > 10 cm (T3) | 11 | Maximum benefit on prior therapy | 3 pts | |
| First line sorafenib | 12 pts | |||
| Risk factors | Prior therapy (median of 2) | 14 pts | ||
| FAP | 4 | |||
| Prior Surgery* | 7 | Duration of Sorafenib (median) | ||
| - Surgery for FAP | − 4/7 | - Entire cohort (months) | 6.4 (1 – 29) | |
| - Surgery for other | − 3/7 | - As 1st line (months) | 4.6 (1 – 29) | |
| Pregnancy | 1 | - As 2nd line (months) | 12 (2 – 26) | |
*
surgery for other reasons before diagnosis of desmoid,
**
SD: Stable Disease by RECIST,
***
minor response: decrease by 10 – 29% by RECIST.